Intercept Pharmaceuticals (ICPT) : The total negative money flow of $4.72 million on Monday indicates selling on strength. The inflow of money on upticks was $20.08 million, compared to $24.8 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.81. The negative money flow of $1.91 million in block trades reveals that the informed traders sold the stock on every bit of price strength.The transaction value of block trade on downtick was $1.91 million. The price action in the Intercept Pharmaceuticals (ICPT) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $165.05 with a gain of $2.06 , a change of 1.26% over the previous days close. The stock registered 1.71% for the week.
Shares of Intercept Pharmaceuticals, Inc. rose by 2.3% in the last five trading days and 10.97% for the last 4 weeks. Intercept Pharmaceuticals, Inc. is up 23.1% in the last 3-month period. Year-to-Date the stock performance stands at 10.51%.
Intercept Pharmaceuticals (NASDAQ:ICPT): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $162.85 and $162.46 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $168.40. The buying momentum continued till the end and the stock did not give up its gains. It closed at $165.05, notching a gain of 1.26% for the day. The total traded volume was 452,288 . The stock had closed at $162.99 on the previous day.
In a related news, The officer (Chief Strategy Officer), of Intercept Pharmaceuticals Inc, Mcminn Rachel had unloaded 125 shares at $176.57 per share in a transaction on August 1, 2016. The total value of transaction was $22,071. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Companys product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials, including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.